Clinuvel Pharmaceuticals Limited (ASX:CUV)
Australia
· Delayed Price · Currency is AUD 10.01
-1.03 (-9.33%)
At close: Feb 27, 2026
Clinuvel Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Operating Revenue | 87.21 | 86.38 | 81.22 | 72.18 | 60 | 42.6 | Upgrade
|
| Other Revenue | 9.74 | 8.63 | 6.96 | 6.14 | 5.72 | 5.72 | Upgrade
|
| Revenue | 96.95 | 95.02 | 88.18 | 78.32 | 65.72 | 48.32 | Upgrade
|
| Revenue Growth (YoY) | 1.36% | 7.76% | 12.58% | 19.17% | 36.02% | 48.37% | Upgrade
|
| Cost of Revenue | 9.99 | 8.48 | 7.73 | 7.52 | 9.25 | 4.17 | Upgrade
|
| Gross Profit | 86.96 | 86.54 | 80.45 | 70.8 | 56.47 | 44.15 | Upgrade
|
| Selling, General & Admin | 32.28 | 30.22 | 22.84 | 15.65 | 13.03 | 11.57 | Upgrade
|
| Research & Development | 7.95 | 7.4 | 2.35 | 1.27 | 1.23 | 0.55 | Upgrade
|
| Other Operating Expenses | -0.02 | -0.02 | -0.56 | -0.02 | -0.22 | - | Upgrade
|
| Operating Expenses | 43.32 | 40.78 | 31.88 | 26.67 | 20.92 | 15.58 | Upgrade
|
| Operating Income | 43.64 | 45.76 | 48.57 | 44.13 | 35.55 | 28.57 | Upgrade
|
| Interest Expense | -5.04 | -4.46 | -4.45 | -3.19 | -2.27 | -1.62 | Upgrade
|
| Interest & Investment Income | 9.43 | 9.43 | 7.32 | 3.91 | 0.44 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -3.83 | 0.83 | -0.76 | 0.74 | 0.6 | -1.37 | Upgrade
|
| EBT Excluding Unusual Items | 44.2 | 51.55 | 50.68 | 45.58 | 34.32 | 25.58 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 0.13 | Upgrade
|
| Pretax Income | 44.2 | 51.55 | 50.68 | 45.58 | 34.32 | 25.71 | Upgrade
|
| Income Tax Expense | 11.66 | 15.38 | 15.04 | 14.97 | 13.44 | 0.98 | Upgrade
|
| Earnings From Continuing Operations | 32.54 | 36.17 | 35.64 | 30.6 | 20.88 | 24.73 | Upgrade
|
| Net Income | 32.54 | 36.17 | 35.64 | 30.6 | 20.88 | 24.73 | Upgrade
|
| Net Income to Common | 32.54 | 36.17 | 35.64 | 30.6 | 20.88 | 24.73 | Upgrade
|
| Net Income Growth | -16.08% | 1.50% | 16.44% | 46.58% | -15.57% | 64.29% | Upgrade
|
| Shares Outstanding (Basic) | 50 | 50 | 50 | 49 | 49 | 49 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 50 | 51 | 52 | 52 | 51 | Upgrade
|
| Shares Change (YoY) | 0.37% | -1.27% | -1.52% | 0.08% | 1.26% | 1.33% | Upgrade
|
| EPS (Basic) | 0.65 | 0.72 | 0.72 | 0.62 | 0.42 | 0.50 | Upgrade
|
| EPS (Diluted) | 0.64 | 0.72 | 0.70 | 0.59 | 0.40 | 0.48 | Upgrade
|
| EPS Growth | -16.35% | 2.86% | 18.11% | 46.65% | -16.74% | 62.42% | Upgrade
|
| Free Cash Flow | 40.08 | 40.8 | 31.48 | 35.88 | 39.44 | 18.41 | Upgrade
|
| Free Cash Flow Per Share | 0.79 | 0.81 | 0.62 | 0.69 | 0.76 | 0.36 | Upgrade
|
| Dividend Per Share | 0.050 | 0.050 | 0.050 | 0.050 | 0.040 | 0.025 | Upgrade
|
| Dividend Growth | - | - | - | 25.00% | 60.00% | - | Upgrade
|
| Gross Margin | 89.70% | 91.08% | 91.23% | 90.40% | 85.92% | 91.36% | Upgrade
|
| Operating Margin | 45.02% | 48.16% | 55.08% | 56.34% | 54.09% | 59.12% | Upgrade
|
| Profit Margin | 33.56% | 38.07% | 40.41% | 39.08% | 31.77% | 51.18% | Upgrade
|
| Free Cash Flow Margin | 41.34% | 42.94% | 35.70% | 45.82% | 60.01% | 38.10% | Upgrade
|
| EBITDA | 44.32 | 46.54 | 49.32 | 44.52 | 35.97 | 29.07 | Upgrade
|
| EBITDA Margin | 45.72% | 48.98% | 55.93% | 56.85% | 54.74% | 60.16% | Upgrade
|
| D&A For EBITDA | 0.68 | 0.79 | 0.75 | 0.4 | 0.43 | 0.5 | Upgrade
|
| EBIT | 43.64 | 45.76 | 48.57 | 44.13 | 35.55 | 28.57 | Upgrade
|
| EBIT Margin | 45.02% | 48.16% | 55.08% | 56.34% | 54.09% | 59.12% | Upgrade
|
| Effective Tax Rate | 26.38% | 29.83% | 29.68% | 32.85% | 39.17% | 3.83% | Upgrade
|
| Revenue as Reported | 102.57 | 105.3 | 95.31 | 82.99 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.